Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425159 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
A Phase 2 study of Generalized Epilepsy, sponsored by Biohaven Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT06425159: Active Phase 2 study of Generalized Epilepsy, sponsored by Biohaven Therapeutics.
NCT06425159 is a Phase 2 study of Generalized Epilepsy that is active but no longer recruiting, run by Biohaven Therapeutics. The registered enrollment target is 242 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06425159, a Phase 2 study of Generalized Epilepsy, is active but no longer recruiting, sponsored by Biohaven Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Primary Outcome
To compare the efficacy of BHV-7000 to placebo as adjunctive therapy for subjects with idiopathic generalized epilepsy with generalized tonic-clonic (GTC) seizures as measured by the time to the second day with a GTC seizure during the double-blind phase
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BHV-7000
Study Locations (20)
Florida
- Nova Clinical Research, LLC - Bradenton
- University of Florida (Jacksonville) - Jacksonville
- Y&L Advance Health Care,Inc d/b/a Elite Clinical Research - Miami
- Serenity Research Center - Miami
- Research Institute of Orlando - Orlando
- Comprehensive Neurology Clinic - Orlando
- Knight Neurology - Rockledge
- Santos Research Center - Tampa
- Encore Medical Research of Weston LLC. - Weston
Arizona
- Barrow Neurological Institute - Phoenix
- ARENSIA Exploratory Medicine - Phoenix
- Center for Neurosciences - Tucson
Illinois
- Northwestern Medical Group, Department of Neurology - Chicago
- Revive Research Institute, Inc. - Elgin
Alabama
- Accel Research - Birmingham
California
- Profound Research LLC - Pasadena
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Georgia
- Augusta University - Augusta
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What the registry record for NCT06425159 still lists
NCT06425159 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% higher).
The record links to 1 condition, with Generalized Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06425159 names 20 study sites across 9 states, led by Florida, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT06425159 about?
NCT06425159 is a clinical study titled "A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures". The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
What is the current status of trial NCT06425159?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2024-06-20. Estimated completion is 2027-07.
What conditions does trial NCT06425159 study?
This clinical trial studies the following conditions: Generalized Epilepsy.
What interventions are being tested in trial NCT06425159?
The interventions under investigation include: Placebo (DRUG), BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06425159?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425159 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06425159's enrollment target sits among peer trials
242 237th of 2000 higher than 1,762 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI